When Life-Saving Vials Turned Deadly: The Blood Betrayal of 1982
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
When Life-Saving Vials Turned Deadly: The Blood Betrayal of 1982
-
ナレーター：
-
著者：
A tiny cluster of three hemophiliacs triggered a federal report in July 1982 that linked their immune collapse to the very clotting medicines keeping them alive - and internal memos later used the word "strong" to describe transmission through plasma products. How did pooled plasma from thousands of donors become a global vector, and who knew it before the public did?
In this episode, we tell how clotting factor concentrate transformed hemophilia care, why pooled plasma manufacturing mattered, and when companies and public health agencies learned that blood products were transmitting immune failure - could corporate decisions have allowed the risk to spread across countries?
Person: Centers for Disease Control
Date: July 16, 1982
Event: CDC report linking immune collapse to clotting factor medication
Company: Cutter Biological
Phrase in memo: "strong"
Intervention: heat-treated product released by a competitor in May 1983
- The CDC published its initial report on three hemophiliacs on July 16, 1982.
- Clotting factor concentrate batches were pooled from thousands to tens of thousands of individual plasma donors.
- Estimated users of clotting factor concentrate in the early 1980s: 6,000-10,000 in the United States.
- Cutter Biological internal letter dated January 1983 stated evidence of transmission through plasma products was "strong."
- In May 1983, a competitor released a heat-treated clotting product before Cutter.
To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.
© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません